Core Viewpoint - Bayer's stock performance has been influenced by multiple factors, with a recent decline in share price reflecting market concerns over ongoing litigation risks and competition from generic drugs [1][3]. Stock Recent Trends - On February 17, 2026, Bayer's stock surged by 6.04% to $14.40 due to settlement news, but subsequently fell for two consecutive days, indicating cautious market sentiment regarding the effectiveness of the settlement [2]. Recent Events - Litigation risks remain: Bayer announced a $7.25 billion plan to resolve Roundup-related lawsuits, but investor concerns persist. Union Investment's portfolio manager noted that the proposal is not seen as a breakthrough, and a new round of lawsuits could emerge if the company does not win in the Supreme Court, which is set to hear oral arguments at the end of April 2026 [3]. - Core products face generic competition: Bayer's key drugs, Xarelto and Eylea, are under pressure from generic competition in 2026, with expectations that this pressure will only ease after 2026. The patent cliff is directly limiting revenue growth [3]. - Cost-saving plans not fully realized: Bayer's DSO operational model aims to save €2 billion annually starting in 2026, but the effectiveness of this plan remains to be seen. The market is focused on whether it can effectively offset litigation and business pressures [3]. Financial Performance - Financial performance under pressure: According to the Q3 2025 financial report, Bayer's revenue was $11.288 billion, with a net loss of $1.125 billion and a net profit margin of -9.97%. Despite achieving a net profit of $1.367 billion in Q1 2025, subsequent quarters reflected negative earnings, indicating business volatility [4].